MedPath

evamisole treatment for children with steroid sensitive nephrotic syndrome.

Recruiting
Conditions
steroid sensitive idiopathic nephrotic syndrome(steroid gevoelig idiopathisch nefrotisch syndroom), relapse (recidief), levamisole, steroid side effects (steroid bijwerkingen),
Registration Number
NL-OMON26305
Lead Sponsor
Academic Medical Center of AmsterdamMeibergdreef 9, 1105 AZ Amsterdam Z-OThe Netherlands
Brief Summary

Davin JC, Merkus MP. - Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Pediatr Nephrol. 2005 Jan;20(1):10-4.

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

1. Primary diagnosis: frequently relapsing idiopathic Steroid Sensitive Nephrotic Syndrome with or without steroid dependency;

2. 2 > Age < 18 years;

Exclusion Criteria

1. Patients previously treated with Levamisole;

2. Patients unresponsive to Cyclosporine or MMF;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint is defined as the time to relapse which is the time between start of the study medication and occurrence of a relapse or, in case of no relapse, time of censoring (12 months after start of trial medication). Only a relapse necessitating prednisone treatment is considered a primary endpoint relapse.<br>Proposed end of the blinded part of the study is in all patients 12 months after start of the study medication.
Secondary Outcome Measures
NameTimeMethod
1. Average quantity in milligrams of steroids administered per month during the study;<br /><br>2. Evaluation whether treatment effect differs with underlying disease process (steroid dependency yes/no) and prior use of disease modifying agents (yes/no);<br /><br>3. Maintenance dose prednisone at time of relapse.
© Copyright 2025. All Rights Reserved by MedPath